| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $41K | — | -62.4% |
| R&D Expense | $6.8M | — | -35.4% |
| SG&A Expense | $6.1M | — | +52.6% |
| Operating Income | -$12.8M | — | +10.7% |
| Net Income | -$12.3M | — | +8.1% |
| EPS (Basic) | -$0.18 | — | +10.0% |
| EPS (Diluted) | -$0.18 | — | +10.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.5M | -51.1% | -64.5% |
| Short-term Investments | $37.5M | -8.1% | -32.8% |
| Accounts Receivable | $191K | +4.9% | -52.8% |
| Current Assets | $47.3M | -21.3% | -42.8% |
| Total Assets | $49.2M | -20.5% | -42.0% |
| Current Liabilities | $14.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.3M | — | +4.0% |
| Investing Cash Flow | $3.3M | — | +122.3% |
| Financing Cash Flow | $105K | — | +3400.0% |
| +8.8% |
| Total Liabilities | $14.5M | -12.3% | +3.8% |
| Stockholders' Equity | $34.7M | -23.5% | -51.0% |